GlassScriptPhysician profile
Christina Finamore
NPI 1245437052
$1,441.56
in general payments reported to CMS, 2019-2025
18 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $54.51 · 2022: $87.40 · 2023: $84.19 · 2024: $548 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $297.76 | 2019-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $235.31 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $190.45 | 2024-2025 | |
| Galderma Laboratories, L.P. | $138.30 | 2019-2025 | Aklief |
| Amgen INC. | $135.15 | 2024-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $62.71 | 2019-2025 | Cabtreo |
| Incyte Corporation | $55.56 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $51.93 | 2022-2024 | Olumiant, Taltz |
| Mayne Pharma Commercial LLC | $49.97 | 2022-2025 | |
| Genzyme Corporation | $46.92 | 2019-2022 | |
| Pfizer INC. | $44.36 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $39.53 | 2019-2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $27.53 | 2019-2020 | |
| Ucb, INC. | $18.28 | 2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $16.39 | 2024 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $15.00 | 2019 | |
| Almirall LLC | $13.03 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $3.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Finamore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.